• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Intensity Therapeutics Inc.

    6/18/25 4:01:16 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INTS alert in real time by email
    424B5 1 intensity-424b5prosuppatmi.htm 424B5 Document
    Filed Pursuant to Rule 424(b)(5)
    Registration No. 333-280681
    PROSPECTUS SUPPLEMENT No. 3
    (To the Sales Agreement Prospectus dated July 11, 2024 and
    the Base Prospectus, dated July 11, 2024)
    INTENSITY THERAPEUTICS, INC.
    Up to $9,650,000
    Common Stock
    We have previously entered into an at the market offering agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) relating to shares of our common stock offered by this prospectus supplement and the sales agreement prospectus dated July 11, 2024 (the “July 11, 2024 sales agreement prospectus”) and the base prospectus dated July 11, 2024 (the “July 11, 2024 prospectus”). In accordance with the terms of the Offering Agreement, we may offer and sell shares of our common stock, $0.0001 par value per share, from time to time through Wainwright acting as our agent (the “ATM Offering”).
    Our common stock is listed on The Nasdaq Capital Market under the symbol “INTS.” On June 17, 2025, the last reported sale price of our common stock on The Nasdaq Capital Market was $0.2859 per share.
    We are filing this prospectus supplement to supplement and amend, as of June 18, 2025, the July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus to increase the maximum aggregate gross sales price of our common stock that may be offered, issued and sold under the Offering Agreement from and after the date hereof to $9,650,000 (the “ATM Offering Size Increase”), not including the shares of common stock previously sold. Under the July 11, 2024 sales agreement prospectus, we initially registered up to $15,000,000 of our common stock for offer and sale pursuant to the Offering Agreement, which was reduced to $7,000,000 on November 20, 2024, and further reduced to $15,000 on June 11, 2025. As of the date of the filing of this prospectus supplement, we have sold 193,816 shares of our common stock that are covered by the July 11, 2024 sales agreement prospectus pursuant to the Offering Agreement for an aggregate gross sales price of $577,831.
    The purpose of this prospectus supplement is to update the July 11, 2024 sales agreement prospectus to reflect the ATM Offering Size Increase. Except as modified by this prospectus supplement, the terms of the ATM Offering remain unchanged, and the Offering Agreement remains in full force and effect.
    As of the date of this prospectus supplement, the aggregate market value of our outstanding shares of common stock held by non-affiliates (the “public float”), was approximately $46,652,656, which was calculated based on our 24,047,761 outstanding shares of common stock held by non-affiliates at a price of $1.94 per share, the closing price of our common stock on the Nasdaq Capital Market on April 21, 2025. During the 12-calendar month period that ends on, and includes, the date of this prospectus supplement, we have offered $5,880,705 of securities pursuant to General Instruction I.B.6. of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our common stock in a public primary offering with a value exceeding more than one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period as long as the aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates is less than $75,000,000. In the event that we may sell additional amounts under the Offering Agreement, we will file another prospectus supplement prior to making such additional sales.
    Our business and an investment in our common stock involve significant risks. These risks are described under the caption “Risk Factors” beginning on pages S-6 and 5 of the July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus, respectively, and in the documents incorporated by reference into the July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus, as well as the risks and uncertainties described in other documents we file with the Securities and Exchange Commission, or SEC.
    Neither the SEC nor any state securities commission has approved of anyone’s investment in these securities or determined if this prospectus supplement, the July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus are truthful or complete. Any representation to the contrary is a criminal offense.
    H.C. Wainwright & Co.
    The date of this prospectus supplement is June 18, 2025.

    Get the next $INTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INTS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INTS
    SEC Filings

    See more
    • SEC Form S-8 filed by Intensity Therapeutics Inc.

      S-8 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/27/25 4:03:08 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Intensity Therapeutics Inc.

      424B5 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/18/25 4:01:16 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/13/25 4:10:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Principal Accounting Officer Wesolowski John M

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:21:05 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Dubin Thomas I H

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:54 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donovan Daniel

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:09 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment.

      6/20/25 9:21:00 AM ET
      $GRAL
      $IMRX
      $INTS
      $ONCY
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Intensity Therapeutics, Inc. Announces Pricing of Public Offering

      SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its underwritten public offering of 6,675,000 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $2,002,500, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock are being offered by the Company. In addition, the Company

      6/11/25 11:46:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

      SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. ThinkEquity is acting as sole book-running manager for the o

      6/11/25 4:06:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      6/7/24 5:29:04 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      2/13/24 4:01:30 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care